Future Prescriber最新文献

This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its current portfolio, and look at its pipeline of new drugs and areas of research interest.

Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd.

This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Novartis and its current portfolio, and look at its pipeline of new drugs and areas of research interest. Copyright © 2010 John Wiley & Sons, Ltd.

Shingles carries a considerable burden to patients and to the health service. The expected introduction of routine shingles vaccination raises hope for reducing this debilitating infection and its complications. Copyright © 2010 John Wiley & Sons, Ltd.

The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non-Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve Schey considers the place of HDACis in future cancer therapy. Copyright © 2010 John Wiley & Sons, Ltd.

Early detection and appropriate management of chronic obstructive pulmonary disease (COPD) may help to reduce the high mortality and morbidity associated with this disease. New pharmacological treatments for COPD, along with the implementation of recommendations of the National Strategy for COPD due for publication later this year, will help to raise the standard of care and improve outcomes for COPD patients. In this article, Professor Price and Rhonda Siddall consider current COPD therapy and look at future treatment options for COPD. Copyright © 2010 John Wiley & Sons, Ltd.

This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Grünenthal and its current portfolio, and look at the current pipeline and areas of research interest. Copyright © 2010 John Wiley & Sons, Ltd.

New data from different tumour types highlight similarities and differences for specialists, as presented at the Cancer Congress Update meeting held in London, July 2009

Promising studies were reported at the 25th congress of the European Committee for Treatment and Research in MS (ECTRIMS), held on 9-12 September 2009 in Düsseldorf, Germany, while data on a new treatment for chronic low back pain was presented at the 6th Triennial congress of the European Federation of Chapters (EFIC) of the International Association for the Study of Pain (IASP), held on 9-12 September 2009 in Lisbon, Portugal. Copyright © 2009 John Wiley & Sons, Ltd.

Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd.